---
schema_version: "secwatch.filing_event.v1"
accession: "0001404644-24-000073"
form_type: "8-K"
ticker: "NGNE"
cik: "0001404644"
company_name: "Neurogene Inc."
filed_at: "2024-06-18T23:59:59+00:00"
generated_at: "2026-06-01T03:51:30.853361+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Neurogene doses first patient in high-dose cohort of NGN-401; safety data positive

## Summary
- First patient in Cohort 2 received high-dose NGN-401 in May 2024; well-tolerated to date.
- Low-dose cohort (3 patients) shows no new treatment-related adverse events; all AEs mild/Grade 1.
- No signs of MeCP2 overexpression toxicity, including in patient with mild genetic variant.
- Company expects interim efficacy data from low-dose cohort in Q4 2024.
- Neurogene is participating in FDA's START Pilot Program to accelerate NGN-401 development.

## SEC filing metadata
- accession: 0001404644-24-000073
- form_type: 8-K
- ticker: NGNE
- cik: 0001404644
- company_name: Neurogene Inc.
- filed_at: 2024-06-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1404644/000140464424000073/0001404644-24-000073-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1404644/000140464424000073/ngne-20240618.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001404644-24-000073
- JSON: https://secwatch.observer/filing/0001404644-24-000073.json
- Plain text: https://secwatch.observer/filing/0001404644-24-000073.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.